Having previously shown that multiple mechanisms, which also involve NK cells, are elicited by ICB therapy, we now asked the question whether DCs contribute to the therapeutic potential of anti-CTLA-4 and anti-PD-1 mAbs in the λ-MYC lymphoma model. Here, MYC is linked to lymphoma.